Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.
Nir PeledWaleed KianEdna InbarIris M GoldsteinMelanie ZemelOfer RotemAnna B RozenblumHovav NechushtanElizabeth DudnikDaniel LevinAlona ZerShoshana Keren-RosenbergShlomit Yust-KatzVered FuchsAreen A RemilahIlan ShelefLaila C RoismanPublished in: Neuro-oncology advances (2021)
Osimertinib demonstrated high efficacy on brain metastases. All trial arms displayed a significant decrease in the number and diameter of target lesions. These findings indicate that osimertinib is effective for Thr790Met-positive and -negative LUAD patients with asymptomatic brain metastases. Therefore, osimertinib should be considered a viable option for EGFR-mutant patients with brain involvement regardless of their Thr790Met mutation status.